Abstract
The cyclin dependent kinase inhibitor p27 binds to and inhibits preferentially S-phase kinases thereby halting cell cycle progression. Loss of p27 expression has been shown to be associated with aggressive behavior in a variety of human epithelial tumors including prostate cancer. In this review, the role of p27 in cell cycle progression as well as its regulation by the ubiquitin-proteasome pathway are discussed. The experimental evidence pointing to the role of p27 as a tumor suppressor gene is outlined. The data generated to date on the prognostic significance of loss of p27 protein expression in human prostate cancers are summarized. Finally, the implications of the changes in p27 expression which occur as a result of androgen ablation in normal and neoplastic prostate are discussed.
Similar content being viewed by others
References
Sherr CJ: Cancer cell cycles. Science 274: 1672-7, 1996
Del Sal G, Loda M, Pagano M: Cell cycle and cancer: critical events at the G1 restriction point. Crit Rev Oncog 7: 127-42, 1996
Kanib A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS 3rd, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-40, 1994
Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-59, 1997
Sherr CJ: Tumor surveillance via the ARF-p53 pathway. Genes Develop 1998; 12: 2984-91
Levine M: p53, the cellular gatekeeper for growth and division. Cell 88: 323-31, 1997
Hatada I, Mukai T: Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse. Nat Genet 11: 204-6, 1995
Matsuoka S, Thompson JS, Edwards MC, Bartletta JM, Grundy P, Kalikin LM, Harper JW, Elledge SJ, Feinberg: Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15.AP Proc Natl Acad Sci USA 93: 3026-30, 1996
Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC, Silverman A, Harper JW, DePinho RA, Elledge SJ: Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 387: 151-8, 1997
Ponce-Castaneda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, Mathew S, Krauter K, Sheinfeld J, Massague: p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. J Cancer Res 55: 1211-4, 1995
Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague: Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extra-cellular antimitogenic signals. J Cell 78: 59-66, 1994
Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78: 67-74, 1994
Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI: A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. Mol Cell Biol 14: 3683-94, 1994
Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP: Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382: 325-31, 1996
Hershko A: Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol 9: 788-99, 1997
Goldberg AL: Functions of the proteasome: the lysis at the end of the tunnel. Science 268: 522-3, 1995
Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-5, 1995
Wilkinson KD. Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J 11: 1245-56, 1997
Gupta K, Copeland NG, Gilbert DJ, Jenkins NA, Gray DA: Unp, a mouse gene related to the tre oncogene. Oncogene 8: 2307-10, 1993
Gray DA, Inazawa J, Gupta K, Wong A, Ueda R, Takahashi T: Elevated expression of Unph, a proto-oncogene at 3p21.3, in human lung tumors. Oncogene 10: 2179-83, 1995
Zhu Y, Carroll M, Papa FR, Hochstrasser M, D'Andrea AD: DUB-1, a deubiquitinating enzyme with growth-suppressing activity. Proc Natl Acad Sci USA 93: 3275-9, 1996
Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE: Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 11: 1464-78, 1997
Pagano M: Cell cycle regulation by the ubiquitin pathway. FASEB J 11: 1067-75, 1997
Jackson PK: Cell cycle: cull and destroy. Curr Biol 6: 1209-12, 1996
Pan Y, Matsuyama H, Wang N, Yoshihiro S, Haggarth L, Li C, Tribukait B, Ekman P, Bergerheim US: Chromosome 16q24 deletion and decreased E-cadherin expression: possible association with metastatic potential in prostate cancer. Prostate 36: 31-8, 1998
MacGrogan D, Bookstein R: Tumour suppressor genes in prostate cancer. Semin Cancer Biol 8: 11-9, 1997
Paul R, Ewing CM, Jarrard DF, Isaacs WB: The cadherin cell-cell adhesion pathway in prostate cancer progression. Br J Urol 79(Suppl 1): 37-43, 1997
St Croix B, Sheehan C, Rak JW, Florenes VA, Slingerland JM, Kerbel RS: E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol 142: 557-71, 1998
Fang F, Orend G, Watanabe N, Hunter T, Ruoslahti E: Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science 271: 499-502, 1996
Koyama H, Raines EW, Bornfeldt KE, Roberts JM, Ross R: Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 87: 1069-78, 1996
St Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS: Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 2: 1204-10, 1996
Zhu X, Ohtsubo M, Bohmer RM, Roberts JM, Assoian RK: Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol 133: 391-403, 1996
Shulze A, Zerfass-Thome K, Berges J, Middendorp S, Jansen-Durr P, Henglein B: Anchorage-dependent transcription of the cyclin A gene. Mol Cell Biol 16: 4632-8, 1996
Thomas GV, Szigeti K, Murphy M, Draetta G, Pagano M, Loda M: Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol 153: 681-7, 1998
Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perimutter RM, Kaushansky K, Roberts JM: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85: 733-44, 1996
Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffinan ES, Ono M, Khanam D, Hayday AC, Frohinan LA, Koff A: Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 85: 721-32, 1996
Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K: Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707-20, 1996
Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ: The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396: 177-80, 1998
Mal A, Poon RY, Howe PH, Toyoshima H, Hunter T, Harter ML: Inactivation of p27Kip1 by the viral E1A oncoprotein in TGFbeta-treated cells. Nature 380: 262-5, 1996
Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle R, Botz JW, Jansen-Durr P: Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 13: 2323-30, 1996
Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilcyznski S, et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/kip1 in human malignancies. Cancer Res 55: 2266-2269, 1995
Pietenpol JA, Bohlander SK, Sato Y, Papadopoulos N, Liu B, Friedman C, Trask BJ, Roberts JM, Kinzler KW, Rowley JD: Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 55: 1206-10, 1995
Stegmaier K, Takeuchi S, Golub TR, Bohlander SK, Bartram CR, Koeffler HP. Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemia. Cancer Res 56: 1413-7, 1996
Hengst L, Reed SI: Translational control of p27Kip1 accumulation during the cell cycle. Science 271: 1861-4, 1996
Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 57: 1259-63, 1997
Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3: 227-30, 1997
Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3: 222-5, 1997
Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, Akiyoshi T. p27 expression and gastric carcinoma. Nat Med 3: 593, 1997
Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3: 231-4, 1997
Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57: 3381-5, 1997
Singh SP, Lipman J, Goldman H, Ellis FH Jr, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M: Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 58: 1730-5, 1998
Lloyd RV, Erikson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW. P27kip1 a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol (in press)
Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM: Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 58: 542-8, 1998
Cheville JC, Lloyd RV, Sebo TJ, Cheng L, Erickson L, Bostwick DG, Lohse CM, Wollan P: Expression of p27kip1 in prostatic adenocarcinoma. Mod Pathol 11: 324-8, 1998
Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, Loda M, Reiter RE: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 159: 941-5, 1998
Cote RI, Shi Y, Groshen S, Feng AC, Cordon-Cardo C, Skinner D, Lieskovosky G: Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 90: 916-20, 1998
Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague J, Scher HI: Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 90: 1284-91, 1998
De Marzo AM, Meeker AK, Epstein JI, Coffey DS: Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol 153: 911-9, 1998
Guo Y, Sklar GN, Borkowski A, Kyprianou N: Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 3: 2269-2274, 1997
Cunha GR, Donjacour A: Stromal-epithelial interactions in normal and abnormal prostatic development. Prog Clin Biol Res 239: 251-72, 1987
van Steenbrugge GJ, van Uffelen CJ, Bolt J, Schroder FH: The human prostatic cancer cell line LNCaP and its derived sublines: an in vitromodel for the study of androgen sensitivity. J Steroid Biochem Mol Biol 40: 207-14, 1991
Isaacs JT: Role of androgens in prostatic cancer. Vitam Horm 1994; 49: 433-502
Leav I, Merk FB, Kwan PW, Ho SM: Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate 15: 23-40, 1989
Ho SM, Damassa D, Kwan PW, Seto HS, Leav I: Androgen receptor levels and androgen contents in the prostate lobes of intact and testosterone-treated Noble rats. J Androl 6: 279-90, 1985
Leav I, Kwan PW, Merk FB, Chang C, Ho SM: Immuno-histochemical and in situhybridization studies of androgen receptor expression in a transplantable andro-genindependent prostatic carcinoma line (MT) of Noble rats. Lab Invest 67: 788-95, 1992
Chen Y, Robles M, Martinez LA, Liu F, Gimenez-Conti IB, Conti CJ: Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ 7: 1571-8, 1996
Kokontis JM, Hay N, Liao S: Progression of LNCap prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12: 941-53, 1998
Minami S, Ohtani-Fujita N, Igata E, Tamaki T, Sakai T: Molecular cloning and characterization of the human p27Kip1 gene promoter. FEBS Lett 411: 1-6, 1997
Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B: Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J 15: 6595-604, 1996
Kokontis J, Takakura K, Hay N, Liao S: Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 54: 1566-73, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Macri, E., Loda, M. Role of p27 in Prostate Carcinogenesis. Cancer Metastasis Rev 17, 337–344 (1998). https://doi.org/10.1023/A:1006133620914
Issue Date:
DOI: https://doi.org/10.1023/A:1006133620914